SCHEMBL6780916

SCHEMBL6780916

C/C(=C/C(=O)Nc1cc(C(=O)NCc2ccccn2)ccc1C(=O)O)c1ccc2ccccc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.61
NAMPT P43490 1/20 0.48
KDM4E B2RXH2 2/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
MAPK14 Q16539 1/20 0.46
RAB9A P51151 3/20 0.46
LMNA P02545 2/20 0.46
NPC1 O15118 2/20 0.46
POLB P06746 2/20 0.46
SORT1 Q99523 1/20 0.44
HPGD P15428 2/20 0.44
HSD17B10 Q99714 2/20 0.44
NR1H4 Q96RI1 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43
PKM P14618 1/20 0.43
ALOX15 P16050 1/20 0.43
NR4A1 P22736 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6783769 0.91 TERT (0.50) TERTNAMPTKDM4EMEN1KMT2A
SCHEMBL6787438 0.87 TERT (0.58) TERTKDM4ERAB9ANPC1NR1H4
SCHEMBL6780709 0.87 TERT (0.68) TERTKDM4EHPGDNR1H4ALDH1A1
SCHEMBL6787318 0.86 TERT (0.62) TERTNAMPTKDM4EMAPK14RAB9A
SCHEMBL6782056 0.85 TERT (0.71) TERTKDM4EMEN1KMT2ARAB9A
SCHEMBL4024580 0.84 TERT (0.59) TERTNAMPTKMT2ALMNAPOLB
SCHEMBL6791942 0.84 TERT (0.69) TERTKDM4EKMT2ARAB9ANPC1
SCHEMBL6785410 0.83 TERT (0.68) TERTKDM4ENR1H4
SCHEMBL4024701 0.83 TERT (0.68) TERTKDM4EHPGDNR1H4ALDH1A1
SCHEMBL6787684 0.83 TERT (0.68) TERTKDM4ENR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885NAMPT 665/4885KDM4E 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.